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Background: The main objectives of this study were to determine the incidence of
echocardiography-detected right ventricle dysfunction (RVD) or pulmonary hypertension
(PHT) and its correlation with computed tomography pulmonary angiography (CTPA) in hemo-
dynamically stable patients with pulmonary embolism (PE), both at diagnosis and after 6
months follow-up.
Methods: Prospective, descriptive, single-center follow-up study. Study population: 103
consecutive patients, with a life expectancy of >6 months, presenting with PE and a systolic
blood pressure 90 mmHg. Echocardiography and CTPA were performed at diagnosis and after
6 months.
Results: At diagnosis, RVD and isolated PHTwere found in 24.5% and 19.6% of patients, respec-
tively. CTPA and echocardiography correlated significantly at diagnosis. However, CTPA could
not predict accurately RVD or PHT. Persistence of RVD and isolated PHT was observed in 7.9%
and 11.8% of cases, respectively, 6 months later. Intraluminal filling defects disappeared in
79%. No new filling defects were seen in any patient. Excluding cases with comorbidities that
might account for PHT, CTPA was normal at the 6th month in 23.1% of patients with and in
87.8% of cases without persistent RVD or PHT, respectively (p< 0.0001).Division, Complexo Hospitalario Xeral-Calde, c/Dr Ochoa, s/n 27004 Lugo, Spain. Tel.: þ34 98296833;
ez@sergas.es, rgolpe@separ.es (R. Golpe).
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CT and echocardiography after pulmonary embolism 1371Conclusions: RVD or PHT are a frequent finding at diagnosis in patients with hemodynamically
stable pulmonary embolism and they persist at 6 months in a significant proportion of cases.
We have observed a relationship between the persistence of residual vascular obstruction in
CTPA and RVD or PHT 6 months after PE.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Venous thromboembolism remains a major health
problem.1 The short-term mortality of pulmonary embolism
(PE) varies widely, ranging from less than 2% in patients
with hemodynamically stable PE (those who present with
normal blood pressure) to more than 50% in patients with
hypotension.2 Echocardiography has been advocated as
a first-line test in hemodynamically unstable patients in
order to promptly start a fibrinolytic therapy.2 However, its
role in patients with hemodynamic stability remains
controversial.3
A minority of patients who suffer PE develop chronic
pulmonary hypertension (PHT). The natural history of this
condition is not well known.4,5 Identifying predictors of the
development of chronic PHT could help to tailor follow-up
of patients with PE. However, few studies have assessed
right ventricle (RV) function and/or pulmonary artery
pressure after PE, and even less papers focused on cases
with hemodynamically stable PE.6 Also, computed tomo-
graphic pulmonary angiography (CTPA) has been estab-
lished as the frontline imaging modality for the diagnosis of
PE. The extent of PE has been proposed as an important
parameter for predicting right ventricle dysfunction (RVD).7
There are no studies that assess and compare both echo-
cardiography and CTPA evolution 6 months after PE.
This study was designed with the main objectives of: (1)
Assessing the prevalence of RVD and/or PHT at diagnosis in
patients with hemodynamically stable PE, (2) defining the
correlation between echocardiography and CTPA, (3)
assessing if CTPA at diagnosis can be used to accurately
predict RVD or PHT, (4) describing the course of RV function
6 months after PE, and (5) evaluating the resolution rate of
pulmonary emboli on CTPA after 6 months. Secondary
objective was to evaluate the predictive value of CTPA and
echocardiography parameters for adverse outcome.Materials and methods
Patients and study design
This was a prospective, descriptive, single-center follow-up
study. One hundred ten patients were considered for
inclusion. The study population consisted of consecutive
patients presenting with PE to our emergency department.
Inclusion criteria were: age> 18 years and confirmed PE by
CTPA. Exclusion criteria were: massive PE (defined as the
presence of two consecutive systolic blood pressure meas-
urements< 90 mmHg measured> 15 min apart); comor-
bidity causing the patient’s physician to predict a 6-month
mortality> 50% (e.g. metastatic cancer, end-stage respi-
ratory disease or heart failure); creatinine clearancelevel< 35 ml/min or a history of allergy to iodinated
contrast media. We decided not to exclude patients with
comorbidity that could be responsible for RVD or PHT (e.g.
COPD, pulmonary fibrosis, cardiac valve disease) because
our intention was to reflect a real-life clinical scenario.
However, these patients were subsequently analyzed
separately. The study was approved by our centre’s ethical
committee, and all patients gave informed consent to
participate.
Protocol
Initial patient assessment included clinical history, physical
examination, electrocardiography, arterial blood gas anal-
ysis, echocardiography, CTPA and lower-limb venous ultra-
sonography. All included individuals were treated with
anticoagulation for the whole 6 months of follow-up, and
fibrinolytic therapy was not used in any of them. All
patients were educated about the signs and symptoms of
recurrent venous thromboembolism and instructed to
return if they noted any. Six months after diagnosis of PE,
patients returned for a new echocardiography and CTPA,
which were performed using the same methods as the first
time.
Echocardiography
The study was done as soon as possible after admission
using a SONOS 5500 (Hewlett Packard, Palo Alto, CA)
ultrasound imaging system with a S4 transducer. In all cases
M-mode, 2-dimensional, Doppler (continuous and pulsed
wave), and colour Doppler was performed with the patient
in the left lateral position. The structure of the mitral,
aortic, tricuspid, and pulmonary valves (different grades of
regurgitation and stenosis were assessed), and the systolic
and diastolic function of the left ventricle (LV) were
systematically assessed.
We assessed if patients had either RVD or isolated PHT.
Individuals with at least one of the following findings were
diagnosed as having RVD: Right ventricle (RV) hypokinesis
(asymmetrical or delayed contraction, usually in the RV
base), paradoxical septal systolic motion or right ventric-
ular dilatation (end-diastolic diameter> 30 mm or right to
left ventricular end-diastolic diameter ratio 1 in apical 4-
chamber view); Pulmonary hypertension was defined as
pulmonary arterial systolic pressure (PASP)> 40 mmHg.6,8
PASP was derived from the right atrioventricular pressure
gradient using peak velocity of tricuspid flow regurgitation
with continuous wave Doppler in the apical four chamber
view and the modified Bernoulli equation.9 Right atrial
pressure was considered equal to 5 mmHg or 10 mmHg
according to whether or not the inferior vena cava
collapsed during inspiration, respectively.10 The examiner
Table 1 Main characteristics of patients.
N 103
Age (years) 69 15 (range: 24e92)
Males (%) 55
SBP (mmHg) 130 (113.5e140)
PaO2 (mmHg) 63 14
PaCO2 (mmHg) 35 6
Cases with
PaO2< 60 mmHg (%)
34
Risk factor por PE (%) None: 53.6
Surgery: 13.6
Traumatism: 3.6
Other causes of
immobility: 18.2
Hypercoagulable states: 0.9
Other: 10
ECG findings (%) Normal: 36.4
S1Q3T3: 23.6
Right bundle branch
block: 9.1
ST segment depression: 2,7
Other: 28.2
SBP: systolic blood pressure; PE: pulmonary embolism.
Results are expressed as mean SD or as median (interquartile
range) unless otherwise indicated.
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patients’ clinical status and CTPA data.
Computed tomographic pulmonary angiography
All CTPA were performed within 6 h of patient admission to
the hospital. One hundredmillilitres of nonionic contrastwas
administered intravenously at an injection rate of 2.5 ml/s
for 40 s. Images were obtained on the same single-detector
scanner (Somatron PQ 2000S; Picker International, Cleve-
land, Ohio, USA). If possible, scanning was performed during
a 32-s breath hold. If patients were dyspneic, spiral CT
angiography was performed during shallow breathing. The
scanswereobtainedusing125 mAand130 kV.A5 mm/s table
feed was used to scan a 16-cm volume in the craniocaudal
direction (pitch of 1.5). An imaging delay of 20 s was used,
and overlapping images were reconstructed every 1.5 mm
and viewed on films at lung and mediastinal settings.
PE was diagnosed by the on-duty radiologist if an intra-
luminal filling defect was seen. For the purpose of the
study, the images were reviewed by an experienced senior
radiologist, who was blinded to the patients’ clinical status
and echocardiography data. The pulmonary obstruction
index was determined according to Qanadli et al.11 The RV
to LV diameter ratio was obtained by computing the ratio
between the widths of the right and the left ventricular
cavities assessed on axial images obtained at the plane of
maximal distance between the ventricular endocardial free
wall and the interventricular septum, perpendicular to the
long axis. The diameter of the main pulmonary artery (PA)
was measured just before the division into its two main
branches.
Definition of clinical end-points
Primary outcomes measures were the incidence of RVD or
PHT at diagnosis, the proportion of persistent RVD/PHT and
the rate of remaining endoluminal filling defects on CTPA at
6 months. Secondary study outcome was a composite defi-
nition of adverse events which comprised all-cause
mortality and thromboembolic recurrence.
Statistical analysis
Normal distribution of data was assessed using the
D’agostino-Pearson test. Data are shown as means SD
(normally distributed data) or median (interquartile range)
(non-normally distributed data), for continuous variables,
and as percentages for categorical variables. For contin-
uous variables, comparisons between different groups were
made using unpaired t-test or Wilcoxon rank-sum test, as
appropriate. Comparisons between baseline and 6th month
results, were made using paired t-test or Wilcoxon signed-
rank test, as appropriate. Chi-square test was used for
categorical variables. Correlation between the Qanadli
score for the vascular obstruction index and PASP was
assessed using Spearman’s rank correlation coefficient.
Receiver-operating characteristic (ROC) curves were con-
structed to assess the value of CTPA parameters to predict
RVD or PHT at diagnosis. A 2-tailed value of p< 0.05 was
considered significant.Results
Clinical follow-up
Main characteristics of patients are summarized at Table 1.
One patient died from fatal PE soon after the diagnosis,
before echocardiography could be performed. Seven
patients were excluded from the study, after their initial
inclusion: in 2 cases, metastatic cancer was diagnosed, and
another 5 patients were lost for follow-up. Therefore, 102
echocardiographies at diagnosis were available for subse-
quent analysis. Excluded patients were not different from
those included in the study regarding age (77 years
(50.2e82.7) versus 74 years (63.7e80), respectively;
pZ 0.70), PaO2 (61 17 mmHg versus 63 14, respec-
tively; pZ 0.81), systolic blood pressure (140 mmHg
(123.7e156.5) versus 130 (113.5e140); respectively,
pZ 0.21) or CTPA vascular obstruction index (42.5%
(23.75e62.5) versus 43.75% (25e65); respectively,
pZ 0.98). During follow-up, one patient died from septic
shock before the 6-month visit. Echocardiography was
repeated at 6 months in the other 101 patients. Follow-up
CTPA could not be performed in 4 cases: two of them had
reactions to contrast medium during the first CTPA, and
venous access could not be obtained in the radiology
service for another 2 patients. Hence, complete follow-up
evaluation with both echocardiography and CTPA was
available in 97 cases. Thromboembolic recurrence (deep
vein thrombosis) was diagnosed in one patient during the
follow-up.
Table 2 Distribution of patients with comorbid conditions that might cause RVD or PHT, at diagnosis and at the 6th month
follow-up.
Diagnosis 6th month
RVD: 25 No comorbidity: 20 RVD: 8 No comorbidity: 6
Comorbidity: 5
- DM: 1
- HM: 1
- IPF: 1
- COPD: 1
- MVI: 1
Comorbidity: 2
- IPF: 1
- COPD: 1
PHT: 20 No comorbidity: 15 PHT: 12 No comorbidity: 8
Comorbidity: 5
- COPD: 2
- MVI: 2
- AVD: 1
Comorbidity: 4
- COPD: 2
- MVI: 2
RVD: right ventricle dysfunction; PHT: isolated pulmonary hypertension; DM: dilated myocardiopathy; HM: hypertensive myocardiop-
athy; IPF: idiopathic pulmonary fibrosis; COPD: moderate to severe chronic obstructive pulmonary disease; MVI: mitral valve insuffi-
ciency; AVD: aortic valve disease (Results are expressed as number of cases).
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RVD was found in 25 patients (24.5% of the 102 initial
echocardiographies). Isolated PHT was found in 20 cases
(19.6%). Ten of the 45 patients with RVD or PHT at diagnosis
had other diseases that could cause RVD or PHT. Table 2
shows the distribution of patients with comorbid condi-
tions (both at diagnosis and 6 months later).
CTPA at diagnosis
CTPA findings are summarized at Table 3. The median value
of the vascular obstruction index was 43.75%. Twenty seven
patients (26%) had an obstruction index> 60%. Twenty four
patients (23%) had a RV/LV ratio> 1.
Relationship between CTPA and echocardiography
at diagnosis
CTPA and echocardiography findings correlated significantly
at diagnosis. Correlation between the vascular obstruction
score and PASP, considering all the patients, was rZ 0.298
(95% CI: 0.099e0.475; pZ 0.04). If patients with comor-
bidities that might account for RVD or PHT are excluded,
correlation is rZ 0.40 (95% CI: 0.20e0.57, p< 0.001).Table 3 CTPA findings at diagnosis.
Obstruction index 43.75% (25e65)
Number (%) of cases with obstruction
index> 60%
27 (26%)
Number (%) of cases with pulmonary
embolism in main pulmonary arteries
56 (54%)
RVD (mm) 41 (30e50)
LVD (mm) 40 (25e42)
Number (%) of cases with RV/LV> 1 24 (23%)
PAD (mm) 25 (20.2e30.7)
RVD: right ventricle diameter; LVD: left ventricle diameter,
PAD: pulmonary artery diameter. Results are expressed as
median (interquartile range) unless otherwise indicated.Values of the vascular obstruction scores were significantly
higher for patients with RVD or PHT. Table 4 shows values of
the Qanadli index for cases with and without RVD-PHT. We
assessed if CTPA could accurately predict RVD or PHT at
diagnosis. Table 5 shows the area under the ROC curve for
the CTPA parameters and the presence of RVD or PHT, for
all the patients, and excluding cases with comorbid condi-
tions. Although the exclusion of cases with comorbidities
increased the values of the area under the curves, these
were always below 0.80.
Six-month follow-up
One of the patients which suffered an adverse outcome
(dead from septic shock) had RVD at diagnosis. One patient
with a CTPA-assessed obstruction index> 60% suffered an
adverse outcome. None of the cases with a CTPA-measured
RV/LV> 1 had an adverse evolution. The distribution of
patients with comorbid conditions according to echocardi-
ography findings at 6th month is summarized at Table 2.
RVD was found in 8 of them (7.9% of the 101 follow-up
echocardiographies, 32% of the cases with RVD at diag-
nosis). Isolated pulmonary hypertension was found in 12
(11.8%) cases. Ten patients (three, if comorbid conditions
are excluded) had values of PASP that were at least
10 mmHg above those found at diagnosis. Fig. 1 shows PASPTable 4 Values of the vascular obstruction index for
patients with and without RVD or PHT.
All the patients RVD 60% (42.5e75) pZ 0.0034
No RVD 36.25% (25e50)
PHT 50% (25e75) pZ 0.0188
No PHT 35% (25e50)
Excluding
cases with
comorbidities
RVD 68.75% (50e75) pZ 0.0002
No RVD 37.5% (25e52.5)
PHT 63.75% (46.2e75) pZ 0.0007
No PHT 35% (25e50)
RVD: right ventricle dysfunction, PHT: pulmonary hypertension.
Results are expressed as median (interquartile range).
Table 5 Area under the ROC curve for CTPA-derived
parameters and RVD or PHT.
All the patients Excluding cases with
comorbidities
RVD OS 0.69 (0.59e0.78) 0.77 (0.67e0.85)
PAD 0.57 (0.46e0.67) 0.66 (0.55e0.76)
RV/LV 0.58 (0.47e0.70) 0.63 (0.50e0.74)
PHT OS 0.63 (0.53e0.73) 0.71 (0.61e0.80)
PAD 0.58 (0.47e0.68) 0.64 (0.53e0.74)
RV/LV 0.60 (0.48e0.71) 0.64 (0.52e0.75)
Results are expressed as area under the curve (95% CI). OS:
vascular obstruction score. PAD: pulmonary artery diameter.
RV/LV: ratio of right ventricle to left ventricle diameter.
Table 6 Percentages of patients with normal CTPA at 6th
month.
All the patients RVD 37% pZ 0.0069
No RVD 84%
RVD or PHT 45% p< 0.0001
Neither RVD
nor PHT
87%
Excluding cases with
comorbidities
RVD 16.6% pZ 0.0008
No RVD 83.7%
RVD or PHT 23.1% p< 0.0001
Neither RVD
nor PHT
87.8%
RVD: right ventricle dysfunction, PHT: pulmonary hypertension.
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cases with comorbidities.
CTPA at the 6th month showed total resolution of the
intraluminal filling defects in 77 of 97 cases (79%). In 18
cases (18%) we found a partial resolution of the vascular
obstruction. In 2 cases (2%), no significant differences from
the CTPA at diagnosis were found. No new filling defects
were found in any patient. Table 6 shows the percentages
of patients with normal CTPA (no residual vascular
obstruction) at 6th month for groups with and without
echocardiographic abnormalities. Percentages of cases
with normal CTPA were significantly higher if no RVD or PHT
were present. The differences between groups were larger
if patients with comorbidities were excluded.
Nine patients had both persistent PHT and a CTPA
without residual vascular filling defects at the 6th month.
Five of these cases had comorbid conditions that could
explain the echocardiographic abnormalities. The remain-
ing 4 cases had moderate values of PASP (44e47 mmHg).
There was no patient with RVD and a normal CTPA at 6th
month. Two patients who did not have PHT at diagnosis
developed it during the follow-up. Both patients had a CTPA
with persistent vascular obstruction. No patient developed
new RVD during the follow-up.
Discussion
This study has found a 24.5% prevalence of RVD after an
episode of hemodynamically stable PE. When cases with
underlying conditions that might be responsible of PHTFigure 1 PASP at diagnosis and the 6-month follow-up for patients
comorbidities).were excluded prevalence was still 19.6%. Additionally, we
have found a 19.6% prevalence of isolated PHT (14.7% after
exclusion of individuals with comorbidities). Previous
reports have found rates of RVD ranging from 30 to 40% in
hemodynamically stable patients with PE.3,12,13 The inci-
dence of RVD is undoubtedly influenced by the criteria used
to diagnose it. Nowadays there is not a uniform definition of
RVD, and while some authors propose a definition that
includes a combination of raised PASP and/or other signs of
RV strain,12,14 others are more restrictive and apply the
term only to criteria like we used in this study. Regarding
PHT, like other authors, we decided to set the upper normal
value of PASP at 40 mmHg.6 This limit has been placed at
30 mmHg in young and non-obese individuals but, since
PASP is influenced by age and body weight9 (mean age was
69 years in our study), it seems reasonable to expect false
positives with this value.
In agreement with other studies, we have found
a significant correlation between CTPA-derived scores and
echocardiography signs of RVD or PHT.12,15e19 This corre-
lation improved when patients with other conditions that
might cause PHT were excluded from the analysis.
However, when we tried to assess if CTPA at diagnosis could
be used to predict RVD or PHT, we found that area under
the curve was too low for all the parameters studied. Thus,
CTPA cannot be used to select patients that can benefit
from an echocardiographic examination.
We have found a 19.8% incidence of persistent echocar-
diographic abnormalities (RVD or isolated PHT), six months
after thediagnosis. Several studies investigated the incidencewithout (A) and with PHT (B) at diagnosis (excluding cases with
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However, PHT was only investigated in patients with either
persistent dyspnea or large residual perfusion defects on
follow-up. Therefore, the true incidence of post-embolic PHT
might have been underestimated. When echocardiography
was systematically performed, persistent PHTrates increased
up to 31%, depending on the cutoff level for PASP.20,22
To the best of our knowledge, the present study is the
first that systematically performed both echocardiography
and CTPA at diagnosis and after 6 months in a cohort of
patients with hemodynamically stable PE. Our findings
extend the current knowledge regarding the course of RV
function and the mechanisms for the persistence of PHT. In
our study 79% of the patients normalized the CTPA, a higher
percentage than expected. Moreover, if we exclude those
cases with another disease that could be responsible for
PHT, only 4 patients at the end of the study had both PHT
and a normal CTPA. They were elderly patients, with
modest values of PASP. Thus, the pulmonary hypertension
in these cases was of doubtful clinical significance. It must
be highlighted that no new cases of RVD were found during
the follow-up and only 2 patients without prior PHT
developed it at the 6th month. Both of them had persistent
residual vascular obstruction. Two recent studies found
larger percentages of cases who either developed RVD or
increased PASP, 6 months after a hemodynamically stable
PE.6,20 Follow-up CTPA was not performed in these studies.
Therefore, recurrence of PE in some patients, although
improbable, cannot be totally ruled-out. It has also been
suggested that the initial PE might initiate a process that
could damage the RV over time.20 Our study offers new
insight regarding the pathogenesis of PHT after PE, and
suggests that persistent intraluminal filling defects in the
vascular bed is a requirement for the presence of persistent
pulmonary hypertension.
We have not found a worse outcome in patients with RVD.
Several studies concluded that echocardiography was not
clearly useful for prognostic stratification of hemodynami-
cally stable patients with PE.3,20,23 However, other research
papers reported an association between RVD and a poorer
outcome.14,24e26 The rate of adverse events in our patients
was low (2.9%). Therefore, our study probably lacks enough
power to detect a prognostic significance of RVD.
In disagreement with other studies,15,27e29 we have not
found a prognostic value of CTPA. Twenty six percent of our
patients had a vascular obstruction score of more than 60%
and 23% had a RV/LV ratio larger than 1, values that have
been associated with a worse outcome.30,31 Other authors
have observed that vascular obstruction scores are a poor
predictor of mortality or adverse outcome.28,32e34
However, because of the low rate of adverse events
among our patients, we cannot discard the usefulness of
CTPA for predicting outcome.
In addition to the low incidence of adverse events, there
are some other limitations for the present study. We did not
use a multi-detector scanner for performing CTPAs. This
might have underestimated the values of the clot load
scores, as small emboli might have been missed. Also, the
echocardiography was not performed immediately after the
episode of PE. Therefore, we have probably missed some
cases that presented with RVD, which resolved during the
first hours after the PE.Despite these limitations, we can conclude that RVD and
PHT are relatively frequent after an episode of hemody-
namically stable PE and they persist in a significant
proportion of patients 6 months later. CTPA could not
accurately predict the presence of echocardiography-
detected RVD or PHT. There seems to be a relationship
between the persistence of residual vascular obstruction
defects and RVD or PHT at 6 months. The development of
new cases of PHT, under anticoagulation therapy, seems to
be an unusual occurrence, and it seems to happen only in
patients that do not normalize CTPA.Acknowledgements
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